https://www.marketscreener.com/quote/stock/MYRIAD-GENETICS-INC-10141/news/Myriad-Validates-Active-Surveillance-Threshold-With-Prolaris-R-for-Men-With-Prostate-Cancer-20382675/?utm_source=telegram&utm_medium=social&utm_campaign=share